Quest Laboratories
Quest Laboratories (QUESTLAB) share price was ₹84.90 at the 28 Oct 2026 close; market capitalisation ₹139 Cr; P/E (TTM) 9.27; sector Healthcare. The share price fell 4.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue fell 30.3% year on year to ₹32.40 Cr and net profit rose 47.9% year on year to ₹2.87 Cr (compared with Mar 2025). Promoters held 66.78% of Quest Laboratories in Sep 2026, unchanged from Mar 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 11:17 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,764.10 | 35.00 | 4,23,267 Cr | 5.06 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,665.50 | 87.72 | 2,56,589 Cr | 15.31 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,591.60 | 72.08 | 1,74,650 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,195.00 | 108.45 | 1,18,599 Cr | 22.38 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,183.70 | 26.34 | 1,18,075 Cr | 4.36 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.50 | 34.72 | 1,11,889 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,366.00 | 32.73 | 1,10,353 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Quest Laboratories (this company) | ₹84.90 | 9.27 | 139 Cr | 1.44 | 0.00% | 15.36% | 20.09% | 114 Cr | 15 Cr |
| Median 8 companies | ₹1,565.05 | 34.86 | 1,18,337 Cr | 4.71 | 0.47% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 86.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.2%
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 116 days to 218 days
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 12.78% · Mar 2026
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 15.25 | 27.37 | 14.84 | 46.45 | 23.18 | 25.62 | 30.61 | 32.4 |
| Expenses | 13.47 | 18.56 | 14.18 | 45.64 | 19.36 | 22.24 | 23.7 | 28.26 |
| Operating Profit | 1.78 | 8.81 | 0.66 | 0.81 | 3.82 | 3.38 | 6.91 | 4.14 |
| OPM % | 11.67% | 32.19% | 4.45% | 1.74% | 16.48% | 13.19% | 22.57% | 12.78% |
| Other Income | 0.16 | 0.68 | 0.3 | 3.41 | 1.85 | 1.42 | 0.57 | -1.31 |
| Interest | 0.13 | 0.37 | 0.04 | 0.37 | 0.64 | 0.58 | 0.47 | 0.16 |
| Depreciation | 0.15 | 0.14 | 0.15 | 0.19 | 0.21 | 0.21 | 0.2 | 0.21 |
| PBT | 1.66 | 8.98 | 0.77 | 3.66 | 4.82 | 4.01 | 6.81 | 2.46 |
| Tax % | 11.45% | 32.41% | 0% | 47.27% | 14.94% | 0% | 40.82% | -16.67% |
| Net Profit | 1.48 | 6.06 | 0.78 | 1.94 | 4.1 | 4.02 | 4.03 | 2.87 |
| EPS (₹) | 0.9 | 3.7 | 0.48 | 1.18 | 2.5 | 2.45 | 2.46 | 1.75 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 30 | 59 | 62 | 83 | 104 | 112 |
| Expenses | 29 | 53 | 54 | 67 | 88 | 94 |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 4.7% | 11% | 13% | 19% | 15% | 16% |
| Other Income | 0 | 0 | 0 | 0 | 4 | 2 |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| PBT | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 18% | 29% | 28% | 30% | 27% | 17% |
| Net Profit | 1 | 4 | 5 | 10 | 14 | 15 |
| EPS (₹) | — | — | — | 8.45 | 8.37 | 9.07 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 66 | 80 |
| Borrowings | 3 | 3 | 4 | 5 | 30 | 8 |
| Other Liabilities | 9 | 22 | 28 | 27 | 10 | 7 |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 112 |
| Fixed Assets | 6 | 7 | 10 | 10 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 7 | 52 | 16 |
| Other Assets | 12 | 27 | 37 | 44 | 58 | 80 |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 112 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 1 | 3 | 4 | 3 | -23 | -11 |
| Investing | -1 | -2 | -4 | -5 | -44 | 35 |
| Financing | 0 | 0 | 0 | 2 | 67 | -24 |
| Net Cash Flow | 0 | 1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 2 | 1 | 2 | -23 | -16 |
| CFO/EBITDA | 103 | 57 | 72 | 46 | -120 | -33 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days Payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 | 218 |
| ROCE % | — | 55% | 47% | 57% | 27% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Quest Laboratories insights
59 extracted metrics + investor summaries across FY21–FY26.
Documents
Frequently Asked Questions about Quest Laboratories
What does Quest Laboratories Ltd do?
Where is Quest Laboratories Ltd (QUESTLAB) listed?
Which sector does Quest Laboratories Ltd belong to?
What is the market capitalisation of Quest Laboratories Ltd?
What is the PE ratio of Quest Laboratories Ltd?
What is the 52-week high and low of Quest Laboratories Ltd?
What is the Return on Equity (ROE) of Quest Laboratories Ltd?
Company Information
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/QUESTLAB.md for Quest Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.